Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

News Opinion CV Team Dispatch

November 2024 Dispatch for the CV Team

L.A. McKeown

November 26, 2024

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Opinion CV Team Dispatch

October 2021 News Roundup

L.A. McKeown

October 01, 2021

News Opinion CV Team Dispatch

July/August 2021 News Roundup

L.A. McKeown

August 01, 2021

News Daily News

Thrombotic Events Frequent Among COVID-19 Patients in ICUs

Michael O'Riordan

October 27, 2020

News Daily News

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Michael O'Riordan

July 13, 2020

News Daily News

Heart Failure Itself, Not Just the Hospital Stay, May Raise Long-term VTE Risk

Caitlin E. Cox

January 14, 2020

Medically Ill Pa+ent Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presentation ESC 2018

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presenter: Alex C. Spyropoulos

August 27, 2018

News Conference News ESC 2018

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

Todd Neale

August 26, 2018

News Daily News

Catheter-Directed Thrombolysis for DVT Increases Bleeding Compared With Standard Anticoagulation

L.A. McKeown

July 24, 2014

News Daily News

Endovascular Therapy for DVT Appears Safe, Effective in Registries

January 22, 2013

Advertisement

November 2024 Dispatch for the CV Team

October 2023 News Roundup

October 2021 News Roundup

July/August 2021 News Roundup

Thrombotic Events Frequent Among COVID-19 Patients in ICUs

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Heart Failure Itself, Not Just the Hospital Stay, May Raise Long-term VTE Risk

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

MARINER Fails to Meet Primary Endpoint Testing Rivaroxaban for Extended VTE Thromboprophylaxis

Catheter-Directed Thrombolysis for DVT Increases Bleeding Compared With Standard Anticoagulation

Endovascular Therapy for DVT Appears Safe, Effective in Registries

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content